"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

"NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

"The Obama administration is poised to spend a lot of money on infrastructure; one important sector is the the nation's electric power grid and the communications system," notes growth stock advisor Dave Dyer.

In his Dave Dayer's Newsletter, he explains, "Some products will win big, others will get nothing, but one company will get more business regardless of which products win: Quanta Services (NYSE: PWR), the leading electrical contractor in the country.

"Quanta's service business stands ready to expand with the infrastructure buildout no matter which products are selected.

"They do design, installation, maintenance, and repair on just about any type of network infrastructure (electric power, telecom, broadband cable, and gas pipelines.) Their moat against competitors is size. They are the largest in their field and that is in no danger of changing.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"HMS Holdings Corp. (NASDAQ: HMSY), which makes its money by correcting errors in Medicaid payments and recovering misspent money, is my top pick for 2009," says growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "This is a company whose fundamentals appear to improve as the economy declines.

"If you think that the unemployment rate will rise in 2009, then you ought to love HMS Holdings. They recently raised their 2009 guidance because they expect higher unemployment.

"The company stated that the unemployment rate is the most important leading indicator of growth in the Medicaid program, which in turn, is one of the most important drivers of their revenue.

"Medicaid is funded by the federal government and administered by the individual states. With 40 of the 50 states under contract, HMSY essentially has a monopoly in this market.

This post is part of a special report, A Dozen Ways to Play an Obama Building Boom.

"Project management firm Hill International (NYSE: HIL) is one of the best ways to profit from the public works projects planned in government stimulus packages," says Dave Dyer.

In his The Dave Dyer Newsletter, he explains, "HIL is a consulting company that provides expertise in the project management area. Their business is a people business, not a business that requires them to invest in a lot of heavy construction equipment.

"I think this gives them three advantages: first, they do not have the long marketing cycle that can last for years on a large project, second, they have greater flexibility to expand or contract as business opportunities change, and third, their fee-based revenue structure is less risky than other compensation models used in the construction industry.

"HIL has two divisions. Its original business, founded in 1976, was a construction litigation support company that supplied expert witnesses and other expertise to construction companies involved in contract disputes.

"They saw early in their history that they could also provide value as a dispute preventer rather than just an after the fact resolver, so they started a project management division.

"The medical arena has long been my favorite sectors; perhaps the best opportunities within the medical sector will be with companies who provide life-saving products for the treatment of serious diseases," says Dave Dyer.

In The Dave Dyer Newsletter, he explains, "That is why Celgene (NASDAQ: CELG) is an excellent choice in this economy." Here's his look at this "recession-resistant" company.

"Celgene is a multinational biopharmaceutical company with a $29 billion market cap and no debt. Revlimid is their blockbuster drug with multi-billion dollar potential. It was first approved by the FDA in 2005, and it has many good years of patent protection ahead of it.

"Revlimid delays the onset of progression of deadly diseases -- leprosy and multiple myeloma. No wonder it is worth $6,000 per month. It is a close derivative of their other drug Thalomid. This drug was used by another company about 50 years ago to treat morning sickness in pregnant women and caused numerous birth defects.

"Despite a recession, we believe that demand for its products will remain strong. For example, if you have multiple myeloma, you would probably do just about anything before missing a payment for your monthly dose of Revlimid.

"Stericycle (NASDAQ SRCL) is a near-monopoly in an essential but unglamorous area, making its an excellent investment in an uncertain economy," says growth stock expert Dave Dyer.

In his Dave Dyer's Newsletter, he states, "If you have something that is dangerous, contaminated, or nasty, and you want it to go away safely, you can rely on SRCL, the leader in medical waste."

"I first recommended the stock almost a year ago, but there is so much good news that I thought this would be a good time to recommend it again.

"And while the stock's 12.4% gain since last August is not spectacular, the S&P 500 is down 14.1% over the same time period -- so SRCL has outperformed the market by a wide margin.

"SRCL is North America's largest provider of medical waste services. In fact, if a major customer wants to contract with a single customer for nationwide services, SRCL is the only choice. Even if the market has not really bottomed out, this is an excellent stock to consider because its business is almost entirely immune to economic cycles.

"Since the market started its downturn early this year, I have avoided all financial stocks and resisted the temptation of value plays," says Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "Well, it is now time to violate both of those prohibitions at once." Here, he looks at a new buy for SLM Corporation (NYSE: SLM), commonly known as Sallie Mae, the nation's largest provider of college loans and savings programs."

"There must be some financial areas that have predictable, growing demand, willing customers who actually have low default rates, and securitization processes that do not involve the type of financial engineering that is only intended to hide risk.

"Well, there is such an area, and it even involves a product that it makes sense to finance since it will actually increase in value over time. I'm talking about student loans.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"The era of personalized medicine is arriving and Genomic Health (NASDAQ: GHDX) is one of the first companies to provide both a successful product and an investment opportunity," says Dave Dyer in his Dave Dyer's Newsletter, referring to his more speculative favorite for 2008.

"The company's genetic test provides a way to determine whether women with early stage breast cancer would benefit from chemotherapy. For 70% of people with early stage breast cancer, minimally invasive surgery and radiation is all that is needed.

"The other 30% have a more aggressive type of cancer and would benefit from also receiving chemotherapy. An objective, quantifiable test based on the genetic characteristics of a specific patient can determine with very high probability which group a patient belongs to.

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Stericycle (NASDAQ: SRCL) is an almost perfect business -- an absolutely essential service, but nobody wants to do it," says Dave Dyer in his Dave Dyer's Newsletter, referring to his more conservative favorite for 2008.

"It is about as close to being a monopoly as you are likely to find, especially in a critical national industry. Stericycle is the acknowledged leader in the unglamorous but necessary task of medical waste disposal.

"It is 12 times bigger than its nearest rival and SRCL is the only vendor able to provide services on a nationwide basis, which means that the large, nationwide customers have only one good option unless they want to deal with multiple vendors.

"The highly regulated nature of its business acts as a convenient barrier to entry by potential competitors. And even if someone does manage to start a competing company, there is a good chance that SRCL will buy them.

A trio of leading advisors are looking outside the US for opportnity in the telecom sector: Nick Vardy sees potential with Telefonica S.A. (NYSE: TEF), David Fried looks south of the border to Telefonos de Mexico (NYSE: TMX) and Dave Dyer recommends the more diversified Emerging Markets Telecommunications Fund (ASE: ETF).

In his Global Bull Market Alert, Nick Vardy explains, "Spanish telecom group Telefonica S.A. is like a corporate conquistador, exploiting its historical links to expand into Latin America. This new Spanish explorer is reaping rich profits for itself and its shareholders.

"Telefonica's global footprint extends across three continents and 23 countries with a total population of 670 million. This conquistador planted its first flag in Latin America 15 years ago and today is the leading telecom in Brazil, Argentina, Chile and Peru.

"For an organization that is already the fifth-biggest telecom company in the world with close to 207 million customers, Telefonica's profits are still expanding at a breathtaking rate.

"Just recently, Telefonica announced that its third-quarter net profit rose 39% year-on-year. Overall, net profit jumped to €4.02 billion from €2.9 billion a year earlier. Also important to us, Telefonica is a stock that has held up remarkably well despite the recent market jitters, recently hitting a record high. We recommend buying the shares at market."